Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06365502
Other study ID # KY2023-156
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 16, 2024
Est. completion date December 2030

Study information

Verified date May 2024
Source Harbin Medical University
Contact Haibo Jia, PhD
Phone 15945685291
Email jhb101180@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this multicenter, prospective, open-label, controlled, randomized trial is to demonstrate the superiority of drug-coated balloon (DCB) treatment on non-flow limited vulnerable plaque as compared to guideline-directed medical therapy (GDMT) in improving clinical cardiovascular outcomes in patients with acute coronary syndrome.


Recruitment information / eligibility

Status Recruiting
Enrollment 1860
Est. completion date December 2030
Est. primary completion date December 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Subjects must be between 18 and 80 years of age 2. Subject must present with acute myocardial infarction or unstable angina planned for PCI 3. Successful stent implantation (i.e., residual stenosis less than 20%) must be done in culprit lesions and any lesions with ischemia evidence (e.g., QFR equal or less than 0.8) 4. Subject must have at least one native non-culprit lesion with visually estimated stenosis of 40-80% and QFR >0.8 5. Target lesion must have a visually estimated diameter of 2.0-4.0 mm and length of = 50 mm 6. Target lesion must have any two of the intravascular imaging criteria of PB >65%, MLA <3.5 mm^2 (OCT) or 4.0mm^2 (IVUS), FCT <75 µm, or maximal lipid arc >180° 7. Subject must provide written informed consent before any study-related procedure Exclusion Criteria: 1. Subject has known hypersensitivity or contraindication to any of the study drugs (including all asprin, P2Y12 inhibitors, one or more components of the study devices, including paclitaxel, etc) that cannot be adequately pre-medicated 2. Subject is receiving immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.) 3. Hypotension, shock, or need for mechanical support or intravenous vasopressors; 4. Creatinine clearance =30 ml/min/1.73 m^2 (as calculated by MDRD formula for estimated GFR) 5. Left ventricular ejection fraction<30% by the most recent imaging test within 30 days before procedure (echo, MRI, contrast left ventriculography or others) 6. Life expectancy <2 years for any 7. Subject is currently participating in another investigational drug or device clinical study that has not yet completed its primary endpoint 8. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results. 9. The target lesion is located within 10 mm of the proximal or distal of stent 10. The target lesion cannot be in the left main coronary artery 11. The target lesion is located in a bifurcation lesion (i.e., the diameter of the branch vessels is >2 mm with >50% of stenosis) 12. The target lesion is located in severe calcification or tortuosity of vessels 13. The target lesion involved in the ostium of LAD, LCX or RCA (within 3 mm of the ostium) 14. The target lesion is located within the bypass graft artery

Study Design


Intervention

Device:
Drug-coated balloon
Non-culprit lesion will be pretreated before DCB treatment. The bail-out stent treatment is permitted if pretreatment failed.
Drug:
Guideline-directed medical treatment
All individuals will receive guideline-directed medical treatment.

Locations

Country Name City State
China Affiliated Beijing Luhe Hospital of Capital Medical University Beijin Beijing
China The Third Second Hospital of Jilin University Changchun Jilin
China Dalian Municipal Central Hospital Dalian Liaoning
China The First Affiliated Hospital of Dalian Medical University Dalian Liaoning
China Daqing Oilfield General Hospital Daqing Heilongjiang
China The Second Affiliated Hospital of Harbin Medical University Harbin Heilongjiang
China The Affiliated Hospital of Neimenggu Medical University Hohhot Neimenggu
China The First Affiliated Hospital of Jiamusi University Jiamusi Heilongjiang
China Shandong Provincial Hospital Jinan Shandong
China Affiliated Hospital of Jining Medical University Jining Shandong
China Mudanjiang Cardiovascular Hospital Mudanjiang Heilongjiang
China The Affiliated Hospital of Qingdao University Qingdao Shandong
China The People's Hospital of Liaoning Province Shengyang Liaoning
China Tongji Hospital Tongji Medical College of HUST Wuhan Hubei
China Yantai Yuhuangding Hospital Yantai Shandong
China Fuwai Central China Cardiovascular Hospital Zhengzhou Henan
China The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan
China Affiliated Hospital of Zunyi Medical University Zunyi Guizhou

Sponsors (2)

Lead Sponsor Collaborator
Harbin Medical University Shanghai Shenqi Medical Technology Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Target lesion failure (TLF) At 24 months
Secondary Target lesion failure (TLF) At 30 days
Secondary Target lesion failure (TLF) At 6 months
Secondary Target lesion failure (TLF) At 12 months
Secondary Major cardiac adverse event (MACE) MACE is defined as the composite of all-cause death, recurrent myocardial infarction, revascularization, unplanned readmission for angina exacerbation or unstable angina At 30 days
Secondary Major cardiac adverse event (MACE) MACE is defined as the composite of all-cause death, recurrent myocardial infarction, revascularization, unplanned readmission for angina exacerbation or unstable angina At 6 months
Secondary Major cardiac adverse event (MACE) MACE is defined as the composite of all-cause death, recurrent myocardial infarction, revascularization, unplanned readmission for angina exacerbation or unstable angina At 12 months
Secondary Major cardiac adverse event (MACE) MACE is defined as the composite of all-cause death, recurrent myocardial infarction, revascularization, unplanned readmission for angina exacerbation or unstable angina At 24 months
Secondary All-cause death Any death will be recorded as all-cause death At 30 days
Secondary All-cause death Any death will be recorded as all-cause death At 6 months
Secondary All-cause death Any death will be recorded as all-cause death At 12 months
Secondary All-cause death Any death will be recorded as all-cause death At 24 months
Secondary Cardiac death and target lesion MI All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Cardiac death is defined as any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment At 30 days
Secondary Cardiac death and target lesion MI All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Cardiac death is defined as any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment At 6 months
Secondary Cardiac death and target lesion MI All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Cardiac death is defined as any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment At 12 months
Secondary Cardiac death and target lesion MI All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Cardiac death is defined as any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment At 24 months
Secondary Cardiac death All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Cardiac death is defined as any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment At 30 days
Secondary Cardiac death All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Cardiac death is defined as any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment At 6 months
Secondary Cardiac death All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Cardiac death is defined as any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment At 12 months
Secondary Cardiac death All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Cardiac death is defined as any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment At 24 months
Secondary Target lesion myocardial infarction Target lesion Myocardial Infarction (TL-MI) and non-TL-MI will be assessed At 30 days
Secondary Target lesion myocardial infarction Target lesion Myocardial Infarction (TL-MI) and non-TL-MI will be assessed At 6 months
Secondary Target lesion myocardial infarction Target lesion Myocardial Infarction (TL-MI) and non-TL-MI will be assessed At 12 months
Secondary Target lesion myocardial infarction Target lesion Myocardial Infarction (TL-MI) and non-TL-MI will be assessed At 24 months
Secondary Periprocedural myocardial infarction Periprocedural Myocardial Infarction (TL-MI) and non-Periprocedural will be assessed. At 30 days
Secondary Periprocedural myocardial infarction Periprocedural Myocardial Infarction (TL-MI) and non-Periprocedural will be assessed. At 6 months
Secondary Periprocedural myocardial infarction Periprocedural Myocardial Infarction (TL-MI) and non-Periprocedural will be assessed. At 12 months
Secondary Periprocedural myocardial infarction Periprocedural Myocardial Infarction (TL-MI) and non-Periprocedural will be assessed. At 24 months
Secondary Periprocedural and non-periprocedural myocardial infarction Periprocedural Myocardial Infarction (TL-MI) and non-periprocedural will be assessed At 30 days
Secondary Periprocedural and non-periprocedural myocardial infarction Periprocedural Myocardial Infarction (TL-MI) and non-periprocedural will be assessed At 6 months
Secondary Periprocedural and non-periprocedural myocardial infarction Periprocedural Myocardial Infarction (TL-MI) and non-periprocedural will be assessed At 12 months
Secondary Periprocedural and non-periprocedural myocardial infarction Periprocedural Myocardial Infarction (TL-MI) and non-periprocedural will be assessed At 24 months
Secondary Target vessel failure (TVF) TVF is defined as the composite of cardiac death, target vessel myocardial infarction and ischemia-driven target vessel revascularization. At 30 days
Secondary Target vessel failure (TVF) TVF is defined as the composite of cardiac death, target vessel myocardial infarction and ischemia-driven target vessel revascularization. At 6 months
Secondary Target vessel failure (TVF) TVF is defined as the composite of cardiac death, target vessel myocardial infarction and ischemia-driven target vessel revascularization. At 12 months
Secondary Target vessel failure (TVF) TVF is defined as the composite of cardiac death, target vessel myocardial infarction and ischemia-driven target vessel revascularization. At 24 months
Secondary Minimal lumen area after DCB treatment Post-procedure imaging examination is required At baseline
Secondary Plaque burden after DCB treatment Post-procedure imaging examination is required At baseline
Secondary FCT after DCB treatment Post-procedure imaging examination is required At baseline
Secondary Lipid arc after DCB treatment Post-procedure imaging examination is required At baseline
Secondary FCT <75 µm after DCB treatment Post-procedure imaging examination is required At baseline
Secondary PB >65% after DCB treatment Post-procedure imaging examination is required At baseline
Secondary PB >70% after DCB treatment Post-procedure imaging examination is required At baseline
Secondary MLA <3.5 mm^2 after DCB treatment Post-procedure imaging examination is required At baseline
Secondary Maximal lipid arc >180° after DCB treatment Post-procedure imaging examination is required At baseline
Secondary Cardiac biomarkers: GDF-15, interleukin-6, interleukin-1ß and ceramide etc. The centers with sample preservation qualifications will be asked to preserve blood samples. At baseline and one-year follow-up
See also
  Status Clinical Trial Phase
Terminated NCT00385138 - Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. Phase 3
Completed NCT01944800 - Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Phase 4
Completed NCT02286544 - Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers Phase 1
Completed NCT02290080 - Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers Phase 3
Completed NCT01405287 - Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT Phase 2
Completed NCT00767507 - Maintenance of Platelet Inhibition With Cangrelor Phase 2
Completed NCT03672097 - Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI) Phase 4
Completed NCT00399880 - Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes N/A
Completed NCT02430493 - Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients N/A
Completed NCT01994577 - Optimum Troponin Cutoffs for ACS in the ED
Completed NCT00313300 - Safety Study of Apixaban in Recent Acute Coronary Syndrome Phase 2
Completed NCT02244710 - EndoTic - Endothelium and Ticagrelor N/A
Active, not recruiting NCT04090281 - Implementing Precision Medicine Approaches to Guide Anti-platelet Selection Phase 4
Active, not recruiting NCT03581578 - VITROS Immunodiagnostic Products hs Troponin I
Recruiting NCT04116931 - OPTImal Management of Antithrombotic Agents: OPTIMA-5 Phase 4
Not yet recruiting NCT06449274 - RESTORE Imaging: an OCT-IVUS Imaging Substudy of RESTORE Trial N/A
Completed NCT02171065 - PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial. N/A
Completed NCT00855257 - Assessment of Endothelial Vasomotricity After Treatment by Nicotinic Acid in Acute Coronary Syndrome Phase 3
Completed NCT02733341 - The Effect of IV Cangrelor and Oral Ticagrelor Study Phase 4
Completed NCT02184884 - Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery